Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 73 clinical trials
Major Adverse Limb Events in Patients With Femoro-popliteal and Below-the-knee Peripheral Arterial Disease Treated With Either Sirolimus-coated Balloon or Standard Uncoated Balloon Angioplasty

The SirPAD trial is an academic, investigator-initiated, single-center, randomized, non-inferiority, open-label clinical trial investigating whether the use of sirolimus-coated balloon catheters in patients with peripheral artery disease of the femoro-popliteal or below-the-knee segment is not inferior to that of uncoated balloon catheters for major clinical outcomes (unplanned major amputation, target …

sirolimus
balloon angioplasty
  • 3 views
  • 13 Apr, 2022
  • 2 locations
CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 4 (SMART-CHOICE4)

This study is multi-center, open label, two-by-two factorial, randomized, noninferiority trial to compare the efficacy and safety of polymer-free cobalt-chromium thin drug-coated stents (BioFreedom Ultra) with biodegradable polymer ultrathin sirolimus-eluting stents (Orsiro Mission) and prasugrel monotherapy after 1-month dual antiplatelet therapy (DAPT) of aspirin plus prasugrel with 12-month DAPT of …

  • 0 views
  • 25 May, 2022
  • 1 location
Everolimus Monotherapy as Immunosuppression After Liver Transplant

Tacrolimus is the standard immunosuppressive drug used to prevent organ rejection post liver transplant. One side effect of Tacrolimus is nephrotoxicity. Everolimus does not have the

  • 0 views
  • 23 Jan, 2021
  • 1 location
Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)

The purpose of this research study is to see what effect the combination of lenvatinib plus everolimus has in local and metastatic renal cell carcinoma to potentially make surgically

RET
renal function tests
growth factor
AKT
renal function
  • 0 views
  • 12 May, 2022
  • 1 location
Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer

This phase I trial studies the side effects and best dose of vandetanib and everolimus when given together in treating patients with cancer that has spread to other places in the body

absolute neutrophil count
metastasis
palliative radiation therapy
cancer
neutrophil count
  • 0 views
  • 28 Jun, 2021
  • 1 location
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

This phase II trial studies how well lenvatinib and everolimus work in treating patients with carcinoid tumors that have spread to other places in the body (advanced) and cannot be removed by

nitrosoureas
progressive disease
neutrophil count
multiple endocrine neoplasia type 1
everolimus
  • 2 views
  • 14 Feb, 2022
  • 1 location
Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function

Tacrolimus is the standard immunosuppressive drug used to prevent organ rejection post liver transplant. One side effect of Tacrolimus is nephrotoxicity. Everolimus does not have the

organ rejection
hepatitis c
treatment regimen
immunosuppression
renal injury
  • 3 views
  • 26 Feb, 2022
  • 1 location
Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma (ENCERT)

cells it can encourage untimely cell growth, cell production, and cell survival. Everolimus is an inhibitor of the mTOR pathway and can decrease the growth and survival of cancer cells. It also prevents

neulasta
left ventricular fractional shortening
ejection fraction
etoposide
monoclonal antibodies
  • 8 views
  • 31 Jan, 2022
  • 4 locations
Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

To study the clinical effect of Trametinib combined with Everolimus and Lenvatinib in the treatment of Recurrent/Refractory advanced solid tumors.

  • 6 views
  • 18 Apr, 2021
  • 1 location
Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial)

This study is designed to determine the safety and efficacy of two calcineurin inhibitor free treatment groups 1) a belatacept, everolimus and early corticosteroid withdrawal (ECSWD

  • 3 views
  • 01 May, 2021
  • 2 locations